Kexing Biopharm (688136.SH): Marketing authorization application for pegylated human granulocyte colony-stimulating factor injection accepted
Kexing Biopharm (688136.SH) announced that recently, the company received the "Notice of Acceptance" issued by the National Medical Products Administration regarding the marketing authorization application for its investigational drug pegylated human granulocyte colony-stimulating factor injection (referred to as "GB-K02"). The company's GB-K02 is indicated for reducing the incidence of infection, manifested as febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs that are prone to cause clinically significant febrile neutropenia.
Kexing Biopharm (688136.SH) announced that recently, the company received the "Notice of Acceptance" issued by the National Medical Products Administration for the marketing authorization application of its investigational drug pegylated human granulocyte colony-stimulating factor injection (referred to as "GB-K02"). The company's GB-K02 is indicated for reducing the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Related Articles
SAINT BELLA GP (02508) repurchased 34,500 shares for HKD 93,100 on October 9.
GEEKPLUS-W (02590) intends to invest RMB 50 million to subscribe for 20% of the enlarged registered capital of Beijing Shenyi.
Zhejiang EV-Tech (301607.SZ)'s major shareholder Changjiang NIO Industry Fund plans to reduce its stake by no more than 2.894%.
SAINT BELLA GP (02508) repurchased 34,500 shares for HKD 93,100 on October 9.
GEEKPLUS-W (02590) intends to invest RMB 50 million to subscribe for 20% of the enlarged registered capital of Beijing Shenyi.
Zhejiang EV-Tech (301607.SZ)'s major shareholder Changjiang NIO Industry Fund plans to reduce its stake by no more than 2.894%.
